company-logoAardvark Therapeutics, Inc. Common Stock$10.46
%
Analyst Rating: Hold

Stock Details

CEO

Tien-Li Lee

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

22

Address

4370 La Jolla Village Drive, San Diego, CA, 92122

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

Top Competitors

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Aardvark Therapeutics, Inc. Common Stock  $10.46

$0

Min Forecast(+0% )

$249.61

Avg Forecast( +0% )

$325

Max Forecast(+0%)

EPS

Revenue

Institutional Holder

Loading institutional holder data...

Congress Tracker 

    Showing 0 of 0 results

    Insider Trading of Key Employees

      Showing 0 of 0 results

      Financial News: AARD